CompletedPHASE2, PHASE3NCT04172441
Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism
Studying Hyperinsulinemic hypoglycaemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Zealand Pharma
- Principal Investigator
- Jelena Ivkovic, MDZealand Pharma
- Intervention
- dasiglucagon(drug)
- Enrollment
- 12 enrolled
- Eligibility
- All sexes
- Timeline
- 2020 – 2022
Study locations (6)
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Cook Children's Medical Center, Fort Worth, Texas, United States
- University Children's Hospital, Düsseldorf, Germany
- University Hospital, Magdeburg, Magdeburg, Germany
- Hadassah Medical Center, Jerusalem, Israel
- Manchester University NHS Foundation Trust, Manchester, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04172441 on ClinicalTrials.govOther trials for Hyperinsulinemic hypoglycaemia
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE3NCT06208215RZ358 Treatment for Congenital HyperinsulinismRezolute
- RECRUITINGPHASE2NCT04732416HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)Hanmi Pharmaceutical Company Limited
- ACTIVE NOT RECRUITINGPHASE3NCT03941236Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital HyperinsulinismZealand Pharma
- RECRUITINGPHASE2NCT0420560418FluoroLDOPA PET Imaging for the Detection and Localization of Focal Congenital HyperinsulinismMiguel Pampaloni
- RECRUITINGPHASE1NCT02021604Fluorodopa F 18 in Congenital Hyperinsulinism and InsulinomaCook Children's Health Care System